nuclear receptor subfamily 2 group E member 1Genealiases: TLL · TLX · XTLL
Q-omics provides the consensus-scored NR2E1 profile across patient tissues and cancer cell-line models. NR2E1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NR2E1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NR2E1 RNA expression shows 11,838 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where NR2E1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR2E1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR2E1 survival associations across molecular data types. NR2E1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR2E1 RNA expression–survival associations across cancer types. High NR2E1 expression shows unfavorable associations in COAD, ACC, SKCM, KICH and LGG, but favorable associations in SCLC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NR2E1 RNA expression.
This table summarizes NR2E1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NR2E1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR2E1 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, UCEC, LUAD and BLCA. The KIRC box plot shows higher NR2E1 RNA expression in tumor versus normal tissue (log2 FC = +0.669, t-test p < 0.001).
This table shows molecular features associated with NR2E1 in patient tissues and cancer cell lines. In patient samples, NR2E1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NR2E1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
